Abstract:

sodiumglucose cotransporter2 (SGLT2) inhibitors are a new class of antihyperglycemic drugs which reduce glucose via inhibition of tubular glucose reabsorption.In addition to lowering glucose,reducing blood pressure and ameliorating glucotoxicity,SGLT2 inhibitors also exert direct effects on intrarenal haemodynamics via tubuloglomerular feedback.By blocking the transport of sodium in the proximal tubular,SGLT2 inhibitors decrease intraglomerular pressure and normalize hyperfiltration,suggesting a renoprotective effect in diabetic kidney disease.Results from recent clinical trials demonstrated that SGLT2 inhibitors reduce the risk of cardiovascular events and the renal composite endpoint.The effects of SGLT2 inhibitors on metabolism and haemodynamics may start a new era in therapeutics for chronic kidney disease.

Key words: sodium-glucose, cotransporter-2 inhibitors, diabetes mellitus, chronic kidney disease, renoprotective effect